**Groups and subgroups (n)** |
**Trienoic conjugates, mmol/L** |
**Lipofuscin pigments, μmol/L ** |
**Before Rx** |
**After 2 months** |
**Before Rx** |
**After 2 months** |
1 (n=74) |
12.93 ± 0.25#© |
9.05 ± 0.21#©* |
1.78 ± 0.05#© |
1.2 ± 0.04#©* |
1А (n=41) |
13.66 ± 0.32©@■ |
9.59 ± 0.25©*@■ |
1.92 ± 0.07©@■ |
1.33 ± 0.05©*@■ |
1B (n=33) |
12.03 ± 0.35©¢® |
8.38 ± 0.31©*¢® |
1.59 ± 0.07©¢® |
1.04 ± 0.04©*¢® |
2 (n=66) |
10.68 ± 0.24© |
7.21 ± 0.21α* |
1.41 ± 0.05© |
0.97 ± 0.03©* |
2А (n=15) |
12.08 ± 0.53©● |
8.24 ± 0.35©*● |
1.63 ± 0.12©● |
1.1 ± 0.07©*● |
2B (n=51) |
10.26 ± 0.24©¤ |
6.92 ± 0.24α*¤ |
1.34 ± 0.05©¤ |
0.94 ± 0.03©*¤ |
3 (n=30) |
7.05 ± 0.22 |
0.85 ± 0.02 |
# - difference significant (p<0.001) when comparing between 1 and 2 group, © - difference was significantly (p<0.05) when compared with group 3, α - difference is not
significant (p>0.05) when compared with group 3, * - difference was significantly (p<0.001) when compared to treatment and after 2 months between the group (subgroup),
@ - significant difference (p<0.05) when comparing between 1A and 2A subgroup, ¢ - significant difference (p<0.01) when comparing between 1B and 2B subgroup,
® - significant difference (p<0.05) when comparing between 1A and 1B subgroup, ¤ - significant difference (p<0.05) when comparing between 2A and 2B subgroup,
■ - significant difference (p<0.001) when comparing between 1A and 2B subgroup, ●- the difference is not significant (p>0.05) when comparing between the 2A and 1B
subgroup |